Bookmark and Share

Compound Summary for: CID 16004692


Also known as: Opsumit; ACT-064992; UNII-Z9K9Y9WMVL; ACT064992; 441798-33-0; CHEBI:76607; ACT 064992
Molecular Formula: C19H20Br2N6O4S   Molecular Weight: 588.2729   InChIKey: JGCMEBMXRHSZKX-UHFFFAOYSA-N
Macitentan was approved in October 2013. It is indicated for patients with pulmonary arterial hypertension, and is marketed under the brand name Opsumit. Macitentan is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle, and, thus, blocks the stimulation of vasculature hypertrophy, inflammation, fibrosis, proliferation, and vasoconstriction. Similar to all drugs acting on the renin-angiotensin system, macitentan is associated with embryo and fetal toxicity, so it should not be used in pregnancy and has special precautions that must be followed for all females of child-bearing age.    From: DrugBank
Show subcontent titlesTable of Contents
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties
_ _